First-Line Therapy for Metastatic RCC Remains Controversial Amid New Approvals

The bar for the standard of care among patients with advanced renal cell carcinoma is set high as various promising combination therapies recently received FDA approval.

Source: CancerNetwork - May 16, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news